Barclays initiated coverage of Hims & Hers with an Overweight rating and $48 price target With the concerns around the sustainability of the company’s compounding strategy now better understood, the firm believes the expectations around the shares have become more reasonable, the analyst tells investors in a research note. The firm added that, looking forward to FY26, it believes the recent addition of other growth drivers help create a more favorable setup for durable growth.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers initiated with an Overweight at Barclays
- Hims & Hers announces entry into Canada
- Cautious Outlook on Hims & Hers Health Amid Acquisition Concerns and Declining Demand
- M&A News: Him & Hers Snap Up ‘Pain Free’ Blood Testing Group YourBio
- Hims & Hers to acquire YourBio Health, terms not disclosed
